Chemical Nameoritavancin
Dosage FormInjection (intravenous; 400 mg)
Drug ClassAntibacterials
CompanyMelinta Therapeutics
Approval Year2014


  • For the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.
Last updated on 7/14/2022

More on this drug: Clinical Trials

Document TitleYearSource
Orbactiv (oritavancin) Prescribing Information.2022Melinta Therapeutics LLC, Lincolnshire, IL

Have we missed a study, or would you like to comment on a study?